177Lu-LNC1009

N/A

Report date: 2025/12/08 11:43:09
NME

Base Information

Drug Name177Lu-LNC1009
Drug Alias Name177Lu-LNC1009177Lu-LNC-1009
ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionPositron-emission tomography enhancersIntegrin alpha-V/beta-3 modulators
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesYantai Lannacheng Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesYantai Lannacheng Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A